PDF-ikonPrintikon

Rolf Billeskov, Post doc

Rolf Billeskov
Statens Serum Institut
Artillerivej 5 , 81/348
2300 København S
3268 3268
E-mail:

Ansvarsområder

  • Pre-clinical development and testing of new vaccines and vaccine strategies against tuberculosis

Forskningsområder

  • Analysis of immune response during different stages of experimental Mycobacterium tuberculosis infection in mice
  • Optimize strategies to improve post-exposure vaccine induced protection against tuberculosis with regards to administration route, timing of immunizations, antigen dose

Udvalgte publikationer

  • Solaymani-Mohammadi S, Lakhdari O, Minev I, Shenouda S, Frey BF, Billeskov R, Singer SM, Berzofsky JA, Eckmann L, Kagnoff MF Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. J Leukoc Biol.2015; In Press, PubMed
  • Billeskov R, J. P. Christensen, Aagaard C, Andersen P, Dietrich J Comparing Adjuvanted H28 and Modified Vaccinia Virus Ankara Expressing H28 in a Mouse and a Non-Human Primate Tuberculosis Model. PLoS One.2013; 8(8), e72185 PubMed
  • Billeskov R, Elvang TT, Andersen P, Dietrich J The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One.2012; 7(6), e39909 PubMed
  • Aagaard C, Hoang TTKT, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med.2011; 17(2), 189-194 PubMed
  • Billeskov R, Grandal MV, Poulsen C, Christensen JP, Winther N, Lundberg CV, Hoang TT, van Deurs B, Song YH, Aagaard C, Andersen P, Dietrich J Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis. Eur J Immunol.2010; 40(5), 1342-1354 PubMed

Publikationer